Liposome Co. anticancer agents
IND reviews for liposomal formulations of doxorubicin (TLC-DOX99) and a platinum derivative (TLC-PLAT23) have been completed by FDA and human testing in the U.S. will begin "shortly" at Roswell Park Memorial Institute and M.D. Anderson Hospital and Tumor Institute. Princeton, N.J.-based Liposome Company announced the status of trials in a Feb. 29 press release.
You may also be interested in...
A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.
The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.
Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.